EQL PHARMA AB Net Asset Momentum
EQL PHARMA AB net asset momentum. EQL PHARMA AB (7JK) recorded a net asset momentum of 20.8% as of March 2026, with net assets of €267.06 Million EUR. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See EQL PHARMA AB (7JK) net assets for net asset value and shareholders' equity analysis.
YoY Momentum
Current Net Assets
Years of Data
Country
Net Asset Momentum of EQL PHARMA AB (2022–2026)
Net asset momentum of EQL PHARMA AB from 2022 to 2026. This chart tracks EQL PHARMA AB's year-over-year net asset growth across 5 annual reporting periods from 2022 to 2026. The most recent momentum reading is +20.8%, with net assets of €267.06 Million EUR as of March 2026. Check tangible equity quality of EQL PHARMA AB to evaluate the tangible quality of the company's equity base.
EQL PHARMA AB Net Asset Momentum by Year (2022–2026)
EQL PHARMA AB net asset momentum by year from 2022 to 2026. The table below shows the complete annual net asset history for EQL PHARMA AB from 2022 to 2026, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and overall valuation, see EQL PHARMA AB market cap and net worth.
| Year | Net Assets (EUR) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2026 | €267.06 Million | €850.89 Million | €583.83 Million | ▲ +20.8% |
| 2025 | €221.03 Million | €808.82 Million | €587.79 Million | ▲ +24.4% |
| 2024 | €177.73 Million | €373.76 Million | €196.03 Million | ▲ +14.8% |
| 2023 | €154.75 Million | €285.70 Million | €130.94 Million | ▲ +25.2% |
| 2022 | €123.63 Million | €237.89 Million | €114.26 Million | — |